G-VAX is a cellular vaccine against prostate cancer. Initial studies have demonstrated activity of G-VAX in prostate cancer patients who have failed hormone treatments (hormone refractory prostate cancer, HRPC). Two national studies of G-VAX for HRPC have been conducted at CORT. The first, VITAL-1, is no longer enrolling patients. This study tested the G-VAX therapy against standard therapy with docetaxel (Taxotere) and prednisone in patients who do not have bone pain related to metastatic disease. The second study, VITAL-2, is continuing at CORT, enrolling patients who have active bone pain related to their metastatic disease. This study tests standard therapy with Taxotere and prednisone with or without the G-VAX vaccine. All patients do receive standard therapy.
The risks of chemotherapy for HRPC in this study are fatigue, nausea, vomiting, muscle or bone aches, sensory neuropathy, fever, allergic reaction, or low blood counts. These risks are those of standard treatment. The risk of G-VAX is injection site swelling and discomfort. For more information on our research studies, visit www.CORTPA.com, or speak with a Study Coordinator at 972-566-5588.
Tags: androgen independent prostate cancer, docetaxel, G-VAX, hormone refractory prostate cancer, immunotherapy, Prostate Cancer, Taxotere, vaccine therapy
